Enanta Pharmaceuticals | ENTA - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
AbbVie USD 645M 69M 2026-03
Amgen USD 95.64B 94.98B 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
AstraZeneca USD 340M 144M 2026-06
BioCryst Pharmaceuticals USD 21.71M 7.58M 2026-06
Biogen USD 72.6M 12.6M 2025-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Halozyme Therapeutics USD 5.59M 80K 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Immunic 197K 222K 2025-12
Incyte USD 582K 13K 2026-06
Insmed USD 18.84M 1.24M 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
J&J USD 43M 25M 2026-03
Karyopharm Therapeutics USD 12.55M 66K 2026-03
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Novavax USD 5.82M 342K 2025-12
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Roche Holding CHF 304M 7.5M 2025-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12